Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of “Hold” from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has received an average recommendation of “Hold” from the eleven analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $40.6667.

Several equities research analysts have recently weighed in on AGIO shares. HC Wainwright increased their price target on Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Royal Bank Of Canada cut Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $57.00 to $28.00 in a report on Wednesday, November 19th. Truist Financial upped their price objective on Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, December 24th. Citigroup increased their target price on Agios Pharmaceuticals from $38.00 to $46.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, The Goldman Sachs Group decreased their target price on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th.

Agios Pharmaceuticals Price Performance

Agios Pharmaceuticals stock opened at $27.59 on Friday. Agios Pharmaceuticals has a 1-year low of $22.24 and a 1-year high of $46.00. The firm has a market capitalization of $1.62 billion, a P/E ratio of -3.88 and a beta of 0.89. The company’s 50-day moving average is $28.13 and its 200 day moving average is $33.00.

Insider Buying and Selling

In related news, CEO Brian Goff sold 18,703 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $506,664.27. Following the completion of the sale, the chief executive officer owned 136,583 shares in the company, valued at $3,700,033.47. This trade represents a 12.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Cecilia Jones sold 2,932 shares of the business’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the sale, the chief financial officer directly owned 37,394 shares of the company’s stock, valued at approximately $1,013,003.46. This trade represents a 7.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 36,262 shares of company stock worth $984,237 over the last ninety days. 4.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AGIO. Bellevue Group AG increased its holdings in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after purchasing an additional 124,586 shares during the period. State Street Corp lifted its holdings in shares of Agios Pharmaceuticals by 37.4% in the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock worth $84,604,000 after buying an additional 845,433 shares during the period. Erste Asset Management GmbH lifted its holdings in shares of Agios Pharmaceuticals by 1.4% in the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock worth $76,343,000 after buying an additional 40,000 shares during the period. Wellington Management Group LLP grew its position in shares of Agios Pharmaceuticals by 485.5% during the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock worth $99,203,000 after buying an additional 2,049,287 shares in the last quarter. Finally, Commodore Capital LP grew its position in shares of Agios Pharmaceuticals by 0.6% during the 3rd quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock worth $93,859,000 after buying an additional 13,287 shares in the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.